Medical Technology / Hospital Equipment & Supplies
Strategic Profile
Technology-driven recurring revenue streams and market share gains are positioning Haemonetics for sustainable margin expansion and robust earnings growth, with international expansion and secular health trends expected to drive long-term demand supporting multi-year revenue acceleration. At a share price of $59.34, the company trades on a trailing P/E of 15.7x versus peers at 32.6x and the wider US Medical Equipment group at 30.7x.
Cyborg Score Rationale
Over the last 12 months, Haemonetics converted $1.3B of revenue into $175.4M of net income with a 13.3% net margin (vs. 9.5% prior year), with 35% year-over-year earnings growth accompanied by more modest 5.5% revenue growth forecasts, indicating margin-driven profitability improvement. The stock trades at a discount to analyst targets ($88) and DCF fair value ($95.34), though high debt levels present risk.
Top Insights
Q3 2026 revenue of $339M and basic EPS of $0.96, with quarterly revenue range between $330.6M-$338M and EPS range of $0.71-$0.96, demonstrating consistent operational execution.
Technology-driven recurring revenue streams and market share gains positioning the company for sustainable margin expansion.
Higher leverage paired with lower P/E multiple suggests balance sheet risk is front of mind for investors.
2026-2028 forecast annual revenue growth of 3.68% lags the US Medical Instruments industry average of 11.52%.
Named Competitors
Blood Management & Plasma Collection — Competing in hospital blood management and plasma collection technologies
Vascular Intervention & Closure — Competing in interventional vascular closure and guidewire technologies
Hemostasis Management — Competing in TEG analyzer systems and transfusion management
Recent Developments
(February 2026) Chris Simon (President and CEO) participating in investor fireside chat at Raymond James Healthcare Conference
(January 2026) Acquisition of Vivasure Medical Limited, a pioneer in fully absorbable vessel closure technology, with $11M in proceeds expected in 2026
(February 2026) Q3 FY2026 earnings reported with strong margin improvement to 13.3% and 35% YoY earnings growth
Open the full interactive Haemonetics Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.